AI in Healthcare and Digital Health Strategic Roundup: Clinical Adoption | Sep 12 – Oct 12, 2026
AI in healthcare is shifting toward clinical adoption, with market trends…
Strategy Wargaming: What FDA's Volixibat Signal Means for Ipsen
This LucidWargames case study uses strategy wargaming to examine why FDA's…
Healthcare AI and Digital Health Strategic Roundup | July 3 – August 2, 2026
Healthcare AI and Digital Health Strategic Roundup exploring Developments and…
AI perception of JAK Inhibitors in Atopic Dermatitis | LucidScope AI Visibility Audit
Key Findings from the LucidScope AI Visibility Analysis Rinvoq dominates AI…
AI perception of Lipid-Lowering Therapies | LucidScope AI Visibility Audit
Key Findings from the LucidScope AI Visibility Analysis The investigational…
How AI Models Are Shaping Perceptions of Cystic Fibrosis Therapies | LucidScope AI Visibility Audit
Key Findings from the LucidScope AI Visibility Analysis of Cystic Fibrosis…
Sickle Cell Gene Therapies Ranked by AI Models | LucidScope AI Visibility Audit
Key Findings from the LucidScope AI Visibility Audit of Casgevy, Lyfgenia,…
AI in Healthcare and Digital Health Today—June 23, 2026
This week’s AI in Healthcare and Digital Health update highlights…
AI in Healthcare and Digital Health Today—June 15, 2026
This week’s AI in Healthcare and Digital Health update highlights…
Lucid Diligence Brief: AlzeCure Pharma Collaboration and Out-Licensing Agreement with Eli Lilly
Lucid Diligence Brief: AlzeCure Pharma Collaboration and Out-Licensing…
Why Lower Reactogenicity Alone Will Not Disrupt the Next-Generation Shingles Vaccine Market
AI-powered wargaming shows why lower reactogenicity may not disrupt the…
AI in Healthcare and Digital Health Today—May 26, 2026
This week’s AI in Healthcare and Digital Health update highlights…